Beth R. Jacobson Claims She Developed the Idea for Treatment of
Multiple Myeloma with Thalidomide, seeks at least 25% of the
profits from sale of THALOMID(R) and REVLIMID(R)

NEW YORK, Aug. 25 /PRNewswire/ -- Beth R. Jacobson (formerly
Beth R. Wolmer) filed suit yesterday against Celgene Corporation
(NASDAQ:CELG) , under the claims of "misappropriation of an idea"
and "unjust enrichment" regarding the Company's sale of thalidomide
(THALOMID and REVLIMID ) for the treatment of multiple myeloma. The
suit alleges that Ms. Jacobson developed the original and novel
idea for treating multiple myeloma with thalidomide and is
therefore entitled to compensation consistent with established
legal precedent. Ms. Jacobson is represented in this suit by
Goodwin Procter LLP.

The suit, which was filed in U.S. District Court in Newark, New
Jersey, seeks a minimum of $300 million as past damages and 25
percent of the future profits resulting from the sale of Celgene's
thalidomide products (THALOMID and REVLIMID ) for the treatment of
multiple myeloma.